[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
Grati H, Jebali MC, Harzallah N, Jameleddine M
Record ID 32018011328
French
Original Title:
SKYRIZI® (Risankizumab) dans le traitement du psoriasis en plaques modéré à sévère chez l’adulte
Authors' results and conclusions:
Clinical and economic implications of SKIRIZI (risankizumab) in the treatment of moderate to severe plaque psoriasis in adult
Authors' methods:
Rapid review of literature
Details
Project Status:
Completed
Year Published:
2022
URL for published report:
https://www.ineas.tn/sites/default/files//SKYRIZI%20ETS%20INEAS.pdf
Requestor:
Regulatory authorities
English language abstract:
There is no English language summary available
Publication Type:
Rapid Review
Country:
Tunisia
MeSH Terms
- Psoriasis
- Adult
- Antibodies, Monoclonal
Keywords
- Psoriasis
- Risankizumab (SKYRIZI®)
- plaque psoriasis
- Efficacy
- cost effectiveness
Contact
Organisation Name:
National Authority for Assessment and Accreditation in Healthcare (INEAS)
Contact Address:
30 Rue Ibn Charaf, Tunis 1002, Tunisia
Contact Name:
Mouna Jameleddine
Contact Email:
monajameleddine@gmail.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.